CVL-354
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | Oral administration |
Drug class | Opioid antagonist; κ-Opioid receptor antagonist |
CVL-354 is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders.[1][2]
It acts as a selective antagonist of the κ-opioid receptor.[1][2] The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor.[2] CVL-354 is taken by mouth.[1] It was originated by Pfizer and is under development by Cerevel Therapeutics.[1] As of September 2022, CVL-354 is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.[1]
See also
- κ-Opioid receptor § Antagonists
- List of investigational antidepressants § κ-Opioid receptor antagonists
References
Categories:
- Articles with short description
- Short description matches Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Experimental drugs
- Kappa-opioid receptor antagonists
- Mu-opioid receptor antagonists
- Synthetic opioids
- Experimental antidepressants
- All stub articles
- Nervous system drug stubs